RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
使用图像分析软件的 CD8 和 PD-1 阳性 T 细胞自动测量方法开发
英文原题：Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
查看英文原题
Development of an Automatic Measurement Method for CD8 and PD-1 Positive T Cells Using Image Analysis Software.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
基于影像软件的自动测量可能是一种简单且有用的工具，用于从 TIL 状态方面评估癌症免疫疗法的治疗效果。
研究思路结论见上方概要
背景
随着使用免疫检查点阻断（ICB）疗法的癌症免疫治疗的进展，需要使用成像分析软件对TIL（肿瘤浸润淋巴细胞）状态进行组织学观察，以评估ICB的抗肿瘤效果。
方法
从结直肠癌和胃癌患者中获取的福尔马林固定石蜡包埋切片，这些患者具有超过500个单核苷酸变异，用抗CD8和抗PD-1抗体进行染色。基于我们自己的算法和成像分析软件，建立了一种自动TIL测量方法，并与人工计数方法进行了比较。
结果
在CD8+ T细胞计数中，手动和自动计数方法之间存在良好的相关性（Pearson检验r=0.738）。然而，在PD-1+T细胞测量中，两组的TIL数量存在较大差异。调整参数设置后，PD-1+T细胞测量中手动和自动方法之间的相关性有所改善（Pearson检验r=0.668）。
展开英文摘要原文
MATERIALS AND METHODS
Formalin-fixed paraffin-embedded sections obtained from colorectal cancer and gastric cancer patients with more than 500 single nucleotide variants were stained with anti-CD8 and anti-PD-1 antibodies. Based on our own algorithm and imaging analysis software, an automatic TIL measurement method was established and compared to the manual counting methods.
RESULTS
In the CD8 + T cell number measurement, there was a good correlation (r=0.738 by Pearson test) between the manual and automated counting methods. However, in the PD-1 + T cell measurement, there was a large difference in TIL numbers in both groups. After adjustment of the parameter settings, the correlation between the manual and automated methods in the PD-1 + T cell measurements improved (r=0.668 by Pearson test).
CONCLUSION
An imaging software-based automatic measurement could be a simple and useful tool for evaluating the therapeutic effect of cancer immunotherapies in terms of TIL status.
论文信息
- 作者
- Miyata H、Akiyama Y、Iizuka A、Kondou R、Maeda C、Kanematsu A、Watanabe K、Ashizawa T
- 第一作者单位
- Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan.Japan
- 通讯作者单位
- Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan y.akiyama@scchr.jp.Japan
- 期刊
- Anticancer research2022 Jan
- 原文标识
- PubMed 34969752 · DOI 10.21873/anticanres.15500